These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35807495)

  • 1. In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and Persistent Antitumor Efficacy When Targeted to the Tumor Site.
    Takahashi-Ruiz L; Morris JD; Crews P; Johnson TA; Risinger AL
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules.
    Field JJ; Pera B; Calvo E; Canales A; Zurwerra D; Trigili C; Rodríguez-Salarichs J; Matesanz R; Kanakkanthara A; Wakefield SJ; Singh AJ; Jiménez-Barbero J; Northcote P; Miller JH; López JA; Hamel E; Barasoain I; Altmann KH; Díaz JF
    Chem Biol; 2012 Jun; 19(6):686-98. PubMed ID: 22726683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antiproliferative evaluation of new zampanolide mimics.
    Chen G; Patanapongpibul M; Jiang Z; Zhang Q; Zheng S; Wang G; White JD; Chen QH
    Org Biomol Chem; 2019 Apr; 17(15):3830-3844. PubMed ID: 30924817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zampanolide and dactylolide: cytotoxic tubulin-assembly agents and promising anticancer leads.
    Chen QH; Kingston DG
    Nat Prod Rep; 2014 Sep; 31(9):1202-26. PubMed ID: 24945566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Distinct Mechanisms of Action of Taxane and Non-Taxane Microtubule Stabilizers from Cryo-EM Structures.
    Kellogg EH; Hejab NMA; Howes S; Northcote P; Miller JH; Díaz JF; Downing KH; Nogales E
    J Mol Biol; 2017 Mar; 429(5):633-646. PubMed ID: 28104363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration.
    Field JJ; Northcote PT; Paterson I; Altmann KH; Díaz JF; Miller JH
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for studying microtubule binding site interactions: zampanolide as a covalent binding agent.
    Field JJ; Calvo E; Northcote PT; Miller JH; Altmann KH; Díaz JF
    Methods Cell Biol; 2013; 115():303-25. PubMed ID: 23973080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 9. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
    Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
    Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
    Bernier C; Soliman A; Gravel M; Dankner M; Savage P; Petrecca K; Park M; Siegel PM; Shore GC; Roulston A
    Anticancer Drugs; 2018 Sep; 29(8):774-785. PubMed ID: 29878901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
    Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
    Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Zampanolide Mimics: Design, Synthesis, and Antiproliferative Evaluation.
    Chen G; Jiang Z; Zhang Q; Wang G; Chen QH
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31952332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of taxane binding to tubulin curved and straight conformations by systematic 3'N modification provides for improved microtubule binding, persistent cytotoxicity and in vivo potency.
    Ma Y; Josa-Prado F; Essif JN; Liu S; Li S; Lucena-Agell D; Chan PY; Goossens K; Hortigüela R; Matesanz R; Wang Y; Gago F; Wang H; Risinger A; Diaz JF; Fang WS
    Eur J Med Chem; 2023 Nov; 259():115668. PubMed ID: 37490800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
    Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in microtubule-stabilizing agents.
    Cao YN; Zheng LL; Wang D; Liang XX; Gao F; Zhou XL
    Eur J Med Chem; 2018 Jan; 143():806-828. PubMed ID: 29223097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.